Short answer
Progyny, Inc. (PGNY) filed its Q2 2026 10-Q quarterly report on Aug 7, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $351M (up 5.3% year over year) with net income of $28M.
Q2 2026 key financials · XBRL
- Revenue
- $351M
- +5.3% YoY · +6.7% QoQ
- Net income
- $28M
- +63.9% YoY · +15.8% QoQ
- Operating margin
- 11.4%
- Gross margin
- 25.5%
- EPS (diluted)
- $0.34
- +78.9% YoY · +17.2% QoQ
Source: XBRL data from the Progyny, Inc. (PGNY) Q2 2026 10-Q on SEC EDGAR. USD.
Progyny, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $350.5M, up 5% YoY from $332.9M, driven by fertility benefits revenue up 8% and Progyny Rx up 1%
- Gross margin 25.5% vs 23.7% YoY; operating margin 11.4% vs 7.3%
- Net income $28.1M vs $17.1M; net margin 8.0% vs 5.1%
- Fertility benefits solution best-performing line, revenue up 8% versus Progyny Rx up 1%
- Covered lives 7.19M vs 6.69M; ART cycles 16,998 vs 16,938
Risk Factors
- Newly added guidance risk triggered by August 6, 2026 third-quarter and full-year guidance
- Competitive consolidation risk from fertility-practice acquisitions and larger integrated healthcare systems
- Regulatory risk from potential PBM reform, increased disclosure requirements, and OIG review of benefit administrators
- Cybersecurity risk from targeted attacks against healthcare platforms, vendors, provider clinics, and specialty pharmacies
- Client concentration risk despite over 600 employers, with significant revenue exposure to technology-industry clients
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Progyny, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.